Possible bi-directional link between ETA receptors and protein kinase C in rat blood vessels by Northover, A. M. & Northover, B. J.
Research Paper
Mediators of Inflammation 4, 55-59 (1995)
POSSIBLE links have been investigated between activation
ofprotein kinase C (PKC) and endothelin (ET) production
by small blood vessels. Perfusion pressures were re-
corded from rat isolated mesenteric artery, with or with-
out the small intestine attached, before and after addition
to the perfusate of either ET-1, ET-3 or the PKC activator
12-deoxyphorbol 13-phenylacetate (DOPPA). Rises in
perfusion pressure in response to ET-1 (10-sM)orDOPPA
(10-6M) were reduced significantlyby pre-treatment with
either the ETA receptor antagonist PD151242 (10-6 M) or
the PKC inhibitor Ro 31-8220 (10-6 M). ET-3 (10
-8 M) had
a significant, albeit small, effect only when the gut was
still attached to the mesentery. Inthis latter preparation
ET-1 and DOPPA increased the permeability of villi
microvessels to colloidal carbon in the perfusate. This
effect ofDOPPAwas reducedby pre-treatment with either
PD151242 or Ro 31-8220, but the effects of ET-1 were
reduced significantly only by Ro 31-8220. ET-3
(10-s M) was without effect. The results suggest a possible
bi-directional link between ETA receptors and PKC in the
intestinal vasculature.
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Introduction
Endothelin (ET) isolated from porcine and from
human endothelial cells (ECs) was shown to consist
of three distinct isopeptides, ET-1, ET-2 and ET-3.
The release of ET-1 from ECs in response to stimu-
lation by angiotensin or vasopressin, or to shear
stress or to cyclical strain has been associated with
the activation of protein kinase C (PKC). In addition,
it has been suggested recently that the release of
ETs, or other vasoconstrictor substances, may be
responsible for the slowly developing
vasoconstriction elicited by phorbol esters in rat
isolated mesenteric arterioles. The present work was
undertaken to seek evidence regarding the possible
involvement of ET in this experimental situation,
since phorbol esters are well known to activate
PKC9,1 and one such has been shown to up-regulate
the mRNA for preproendothelin-1 in cultured ECs. 11,12
Phorbol esters have also been shown to increase the
permeability to injected colloidal carbon of
microvessels in rat small intestinal villi in vitro.7,
Thus, the effects of ET-1, ET-3 and 12-deoxyphorbol
13-phenylacetate (DOPPA) on perfusion pressure in
rat mesenteric arterioles and on the permeability of
microvessels to colloidal carbon in rat villi have been
compared. In addition, the effects of pre-treatment
with PD151242, an ETA receptor antagonist,
14 and Ro
31-8220, a specific PKC inhibitor,5 prior to exposure
to ET-1 or DOPPA have been examined.
Methods
The two techniques used in the present experi-
ments have been described in detail elsewhere. 7,8,16
For both preparations rats weighing 350-500 g were
killed by inhalation of chloroform vapour, and the
anterior mesenteric artery then cannulated. Subse-
quently, the mesentery, with or without the small
intestine attached to it, was removed to an organ
bath containing 50 ml of a physiological salt solution
(PSS) at 37C. The blood vessels were flushed with
fresh PSS from a reservoir at 37C via a roller pump
until free of visible blood, and then one or other of
the following two procedures was used.
Isolated mesentery: The rate of flow of perfusate was
set to give a perfusion pressure of approximately 35
mmHg. The volumes of PSS in the organ bath and in
the reservoir were then adjusted to 50 ml in each
case, and re-circulation of PSS commenced. When
appropriate, PD151242 or Ro 31-8220 was added to
the reservoir to give the required concentration. After
10 min of perfusion in this way, the perfusion pres-
sure was noted and then ET-1 or ET-3 or DOPPA was
added to the reservoir. Perfusion pressures were
recorded at 1 min intervals for the next 15 min.
Taking the perfusion pressure at time zero as 0, the
rises during the 15 min agonist treatment were calcu-
lated. The PSS had the following composition (mM):
NaC1 138, KC1 5, NaHCO 10.1, MgC12 1.06, NaHiPO4
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0.416, CaCl22, glucose 10 and pH 7.4, and was gassed
throughout with 95% O2 and 5% CO2.
Mesentery with small intestine attached: The method
was similar to that described above except that the
rate of flow of perfusate was set at 10 ml/min before
re-circulation of perfusate began, and gelatin (2%)
was present in the PSS throughout to reduce oedema
formation in the gut. After 10 min of re-circulation of
the gelatin-containing perfusate (GPSS), with or
without added PD151242 or Ro 31-8220, the
perfusion pressure was noted and either ET-1 or ET-
3 or DOPPA was added. Perfusion pressures at i min
intervals were recorded for 5 min, after which fresh
GPSS was perfused for 1 min, followed by a bolus of
0.5 ml colloidal carbon suspension injected near the
cannula. 16 After a further 5 min period of perfusion
with GPSS, 2 ml rat washed red blood cells were
injected to provide a visual check that vessels in the
gut wall were patent. Then the preparation was
removed from the organ bath and six pieces of small
intestine, each about 4 cm long, were cut, starting
from the caecal end. Each was flushed with normal
saline, opened lengthways and stapled to a xylene-
resistant coverslip. After fixing in formal saline, dehy-
drating in graded alcohols and clearing in xylene
overnight, the specimens were mounted, mucosal
surface uppermost, in DPX mountant. Five areas per
coverslip were photographed using Ilford FP4 black
and white film at xl00 magnification. Negative micro-
graphs were then subjected to image analysis, using
a Seescan system (Cambridge, UK), to assess the
amount of colloidal carbon trapped in the villi
microvessels, as described in detail earlier. 16 A mean
value for each piece of small intestine was calculated
and used to give a mean value for each animal. Mean
values for each treatment group were then compared
statistically. The mean rises in perfusion pressure
recorded at the end of the 5 min period of ET-1, ET-
3 or DOPPA treatment (taking that at time zero as 0)
were also compared.
Statistical analysis: Bonferroni’s test for comparing
more than one treatment group with a single control
group was used.
Chemicals used: ET-1 and ET-3 were obtained from
Sigma Chemical Co., Poole, UK; DOPPA was ob-
tained from Calbiochem-Novachem, Nottingham,
UK; PD151242 was a gift from Dr A. Doherty, Parke
Davis, Ann Arbor, MI, USA; Ro 31-8220 was a gift
from Dr G. Lawton, Roche Products, Welwyn Garden
City, UK; DPX mountant was obtained from BDH,
Poole, UK; gelatin was obtained from Thornton Ross,
Huddersfield, UK; ThermanoxR xylene-resistant
coverslips were obtained from Nunc Inc., Naperville,
IL, USA; and colloidal carbon (Gunther Wagner,
batch C11/1431a) was obtained from Pelikan Inks,
Hanover, Germany. DOPPA and Ro 31-8220 were
dissolved in dimethyl sulphoxide, which, in the con-
centration used, was biologically inert; ET-1, ET-3
and PD151242 were dissolved in water, the latter
with the aid of a little NaiCO3. The dose volume used
was 0.2 ml.
Results
In the isolated mesentery without small intestine
ET-1 (10-8 M) caused a very marked, but slow rise in
perfusion pressure, which reached a peak after 13
min of perfusion (Fig. 1). The response was com-
pletely abolished by pre-treatment with PD151242
(10- M) and significantly reduced by pre-treatment
with Ro 31-8220 (10-M). DOPPA(10-M) also caused
a gradual rise in perfusion pressure, confirming re-
suits from earlier work. This response was signifi-
cantly reduced by pre-treatment with PD151242,
whereas pre-treatment with Ro 31-8220 was shown
previously to abolish the effect. Perfusion of the
mesenteric arterioles with ET-1 (10-9 M) generated a
maximum rise of only 6.5 + 2.6 mmHg. Perfusion
with PSS alone (controls), or ET-3 (10-8 M), PD151242
alone or Ro 31-8220 alone had no effect on perfusion
pressure over a 15 min period.
Perfusion of the vasculature in the isolated
mesentery with its small intestine still attached
150
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FIG. 1. Changes in perfusion pressure in arterioles of rat isolated
mesentery during perfusion with ET-1 (10 M) or DOPPA (10 M) in the
presence or absence of PD151242 (10 M) or Ro 31-8220 (10 M). *A
significant difference exists compared with ET-1 alone, or "compared with
DOPPA alone (p < 0.05, Bonferroni’s test). Data points (+ S.E.M.) are
derived from three to five observations.
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yielded results which were somewhat different from
those obtained with the mesentery alone. Perfusion
with GPSS containing either ET-1 (10-SM) or DOPPA
(10-
M) resulted in modest but highly significant rises
in perfusion pressure (Table 1). ET-3 (10-8M)also
evoked a significant although much smaller pressor
effect. ET-1 (10-9M) was again inactive in this respect
(Table 1). Pre-treatment with either PD151242 or Ro
31-8220 significantly reduced the effects of both ET-
1 (10-M) and DOPPA (10-M).
ET-1 (10-M) was found to be less active than
DOPPA when assessed for its ability to induce col-
loidal carbon leakage in villi microvessels (Table 2),
although both compounds induced effects that were
significantly greater than control values. Pre-treat-
ment with Ro 31-8220 significantly reduced the ef-
fects of both ET-1 and DOPPA, but PD151242, while
tending to reduce the effects of ET-1, only signifi-
cantly reduced the effects of DOPPA (Table 2). ET-
1 (10-9M) and ET-3 (10-M) did not significantly
affect the leakage of colloidal carbon (Table 2).
Discussion
The three ET isopeptides that have been de-
scribed, act upon two ET receptors, ETa and ETB.
17
ETa receptors have a higher affinity for ET-1 and ET-
2 than for ET-3, whereas ETB receptors have a similar
affinity for all three isopeptides. In arterial blood
vessels activation of ETa receptors is associated with
smooth muscle contraction, whereas activation of
ETu receptors sometimes produces smooth muscle
relaxation, the latter possibly via the release of nitric
oxide. TM Coupling of both types of ET receptor to
phospholipase C via a G protein has been demon-
strated.9 However, in human and rabbit saphenous
veins, stimulation of both ETa and ETu receptors is
associated with smooth muscle contraction,
2,21 the
ETa-mediated response being PKC-dependent and
the ETu-mediated response being PKC-independ-
ent. 20
The present results, using the mesenteric vessels,
confirm other reports that ET-1 is a more potent
vasoconstrictor than ET-3, 3, ,1-,. and suggest that in
isolated mesenteric arterioles the constrictor effect of
ET-1 is mediated via ETa receptors, since it is abol-
ished by pre-treatment with the specific ETa receptor
antagonist PD151242, and significantly reduced by
pre-treatment with the specific PKC inhibitor Ro 31-
8220. The virtual lack of effect of the same concen-
tration of ET-3 in this situation also suggests the
absence of functionally important ETu receptors in
mesenteric arterioles. Evidence from other workers
indicates that ETa receptors are located mainly on the
arterial side of the circulation and ETB receptors on
the venous side, ’4 although there are variations be-
tween species and organs.’,24
When the small intestine remains attached to the
mesentery, capillaries and venules, as well as
arterioles, are involved in the perfusion. In the light
of work cited above4 this would provide an oppor-
tunity for stimulation of ETu receptors, which might
Table 1. Effects of ET-1, ET-3 and DOPPA on perfusion pressures in rat isolated mesenteric and small intestinal vessels in the presence
and absence of PD151242 (10-6 M) or Ro 31-8220 (10-6 M)
Treatment Alterations in perfusion pressure (mmHg) after 5 min perfusionab
Concentration (M) n GPSS n GPSS + PD151242 n GPSS + Ro 31-8220
Control 10 -2.70 + 0.90 3 -2.33 + 0.33 4 -0.5 + 1.19
ET-1 10-6 7 32.71 + 2.50 4 6.75 + 3.33 4 3.75 + 0.75
ET-1 10-9 4 0.25 + 0.85
ET-3 10-6 5 2.80 + 0.58
DOPPA 10-6 8 36.75 + 7.34 5 14.80 +/- 2.96 5 13.2 +/- 2.69,"
aPerfusion pressure at the beginning of the 5 min perfusion period was taken as 0. Results are mean +/- S.E.M. cp < 0.05 (Bonferroni’s
test) compared with control values. p < 0.05 (Bonferroni’s test) compared with agonist alone. "Value taken from Reference 8.
Table 2. Leakage of colloidal carbon in microvessels of villi in the rat small intestine in vitro in response to ET-1, ET-3 or DOPPA, and the
effects of pre-treatment with PD151242 (10-6 M) or Ro 31-8220 (10-6 M)
Treatment Amount of CC, determined by image analysis, assessed as % of frame area
Concentration (M) n GPSS n GPSS + PD151242 n GPSS + Ro 31-8220
Control 10 1.05 +/- 0.16 3 1.20 +/- 0.08 4 0.83 +/- 0.10
ET-1 10-6 7 2.05 +/- 0.28 4 139 +/- 0.38 4 0.80 +/- 0.11
ET-1 10-9 4 1.62 +/- 0.49
ET-3 10-6 5 0.65 +/- 0.11
DOPPA 10-6 8 3.74 +/- 0.54 5 2.18 +/- 0.24 5 0.90 +/- 0.12,"
"Each frame represents one negative micrograph magnified approximately 20 times. Results are given as mean +/- S.E.M. cp < 0.05
(Bonferroni’s test) compared with control value. p < 0.05 (Bonferroni’s test) compared with agonist alone. "Value taken from
Reference 8.
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then have a relaxant effect
18 in addition to the con-
tracting effect brought about via arterial ETA
receptors. Activation of two such opposing effects
might explain the smaller rise in perfusion pressure
brought about by ET-1 (32.75 + 2.50 mmHg after 5
min of perfusion in the mesentery plus small intes-
tine, compared with 85.80 + 11.60 mmHg after 5 min
perfusion in the mesentery alone). Alternatively, or in
addition, differences in perfusion pressure rises in
the two preparations may reflect differences in the
flow rates of perfusate used.
PKC-dependent actions of ETs in native vascular
smooth muscle2,25,26 and in cultured vascular smooth
muscle cells27,28 have been demonstrated, as has a
release of ETs by activation of PKC by phorbol
esters. 11,12 Therefore, since the effects ofDOPPA were
reduced in both preparations used in the present
work, by pre-treatment with either the ETA receptor
antagonist or the PKC inhibitor, the possibility of a
bi-directional link between these two processes
arises. On the basis of present evidence, however, it
is not possible to distinguish between mediation by
ET-1 or ET-2, or by a mixture of ET-1 and ET-2, in.
these situations.
A similar link may also be involved in the DOPPA-
and the ET-1 induced increases in vascular perme-
ability that were manifest as a leakage of colloidal
carbon into microvessel walls in small intestinal villi
(Table 2). However, while ET-3 (10-8 M) did not
increase colloidal carbon leakage in the present ex-
periments, other workers have shown that an appli-
cation of ET-3 (10-1 M) in conjunction with an ETA
receptor antagonist increased microvascular perme-
ability to FITC-labelled albumin in rat mesentery. 29 In
vivo, the ET-l-induced increase in vascular perme-
ability to Evans Blue dye appeared to be mediated
via release of platelet-activating factor3 but we have
no information at the moment as to whether this also
operated in our experimental situation. We have, in
fact, shown that DOPPA-induced colloidal carbon
leakage was enhanced by pre-treatment with
indomethacin13 suggesting a possible inhibitory ef-
fect of prostanoids.
Increases in microvascular permeability in re-
sponse to various inflammatory agonists have been
attributed to an increase in cytoplasmic Ca2+ levels in
Ecs, either as a result of influx from the extracellular
medium or by release from intracellular stores. 31,32
Such increases in Ca
2/ levels have been demonstrated
in response to bradykinin,33,34 to platelet activating
factor35 and, more recently, to ET-1,36,37 and are
thought to lead to EC contraction. This results from
an actomyosin shortening, brought about by
phosphorylation of myosin light chains via myosin
light chain kinase, which is a Cai/-calmodulin-de
pendent process. 38 Myosin light chains can also be
phosphorylated by PKC,39 as can the thin-filament
regulatory protein caldesmon.4 Therefore, previous
reports showing that stimulation of ET-1 receptors
induces a phosphorylation of myosin light chains
and of caldesmon in arterial smooth muscle41,42 are
important in the present context, and support the
suggested bi-directional link between activation of
ETA receptors and activation of PKC.
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